<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545947</url>
  </required_header>
  <id_info>
    <org_study_id>CC-223-NSCL-001</org_study_id>
    <secondary_id>2011-005290-23</secondary_id>
    <nct_id>NCT01545947</nct_id>
  </id_info>
  <brief_title>Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this first study combining an investigational dual mTOR inhibitor,
      CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to
      establish a maximum tolerated dose level for each combination in order to evaluate their
      effects in future clinical trials for advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Cmax</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Pk-Maximum observed concentration in plasma (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-AUC</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Tmax</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>PK-Time to maximum concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-T1/2</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>PK-Terminal half-life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-CL/F</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>PK-Apparent total body clearance (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Vz/F</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>PK-Apparent volume of distribution (Vz/F)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mTORC1 and mTORC2 pathway biomarkers</measure>
    <time_frame>Up to 15 months.</time_frame>
    <description>The effect of treatment on mTORC1 and mTORC2 pathway biomarkers in blood and tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC-223 metabolite, M1</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>CC-223 metabolite, M1, will be characterized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Tumor Response Rate using RECIST 1.1 (Eisenhauer, 2009)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants surviving without tumor progression</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants surviving without tumor progression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CC-223/erlotinib concurrent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-223/oral azacitidine concurrent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-223/oral azacitidine sequential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223, erlotinib</intervention_name>
    <description>Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotinib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy</description>
    <arm_group_label>CC-223/erlotinib concurrent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223, oral azacitidine</intervention_name>
    <description>Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy</description>
    <arm_group_label>CC-223/oral azacitidine concurrent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223, oral azacitidine</intervention_name>
    <description>Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy</description>
    <arm_group_label>CC-223/oral azacitidine sequential</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, 18 years or older, with histologically or cytologically-confirmed,
             Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with tumor progression following at
             least one prior treatment regimen [(either chemotherapy or an Epidermal Growth Factor
             Receptor inhibitor (EGFR)] for advanced disease. There is no restriction on the number
             of prior treatment regimens allowed.

          2. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 to 1.

          3. Adequate organ function.

          4. Adequate contraception (if appropriate).

          5. Consent to retrieve archival tumor tissue.

          6. Consent to repeated tumor biopsy (dose expansion phase).

        Exclusion Criteria:

          1. Prior systemic cancer-directed treatments or investigational drugs within 4 weeks or 5
             half lives, whichever is shorter except erlotinib which may be continued with
             intervention in subjects allocated in Arm A.

          2. Symptomatic central nervous system metastases.

          3. Acute or chronic pancreatitis.

          4. Persistent diarrhea or malabsorption &gt; Grade 2, despite medical management.

          5. Impaired cardiac function or significant cardiac disease.

          6. Diabetes on active treatment, fasting blood glucose &gt; 126 mg/dL, (glycated
             haemoglobin) HbA1c &gt; 6.5%.

          7. Known Human Immunodeficiency Virus (HIV), chronic hepatitis B or C infection.

          8. Prior treatment with an investigational dual target of ripamycin 1 (TORC1)/ target of
             ripamycin 2 (TORC2), Phosphatidylinositol 3-Kinase (PI3K), or protein kinase B (Akt)
             inhibitor. Prior treatment with analogs of rapamycin (rapalogs) is allowed.

          9. Major surgery &lt; 2 weeks prior to starting study drugs. No specific wash out is
             required for radiotherapy. Subjects must have recovered from any effects of recent
             therapy that might confound the safety evaluation of study drug.

         10. Pregnant or breastfeeding, inadequate contraception.

         11. History of concurrent second malignancies requiring ongoing systemic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen Hege, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center, Inflammatory Bowel Disease Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>9411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers - Medical City</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d´Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del RocíoServicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Cancer of the Lung</keyword>
  <keyword>Stage IIIB Non-Small Cell Lung Cancer</keyword>
  <keyword>IV Non-Small Cell Lung Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

